{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:44:15Z","timestamp":1789685055876,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":292,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100483","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T04:57:03Z","timestamp":1634878623000},"page":"100483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer\u2013Real-world data from a single center in India"],"prefix":"10.1016","volume":"29","author":[{"given":"Shalabh","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr. Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SVS","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayanand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep R","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"dju055","key":"10.1016\/j.ctarc.2021.100483_bib0001","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst. [Internet]"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100483_bib0002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/ijc.IJC_73_18","article-title":"Clinicopathological profile of breast cancer\u2013An institutional experience","volume":"55","author":"Gogia","year":"2018","journal-title":"Indian J. Cancer"},{"issue":"14","key":"10.1016\/j.ctarc.2021.100483_bib0003","first-page":"4332","article-title":"HER-2\/neu amplification predicts poor survival in node-positive breast cancer","volume":"50","author":"Borg","year":"1990","journal-title":"Cancer Res."},{"issue":"9712","key":"10.1016\/j.ctarc.2021.100483_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"S1","key":"10.1016\/j.ctarc.2021.100483_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","article-title":"Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer","volume":"11","author":"Baselga","year":"2006","journal-title":"The Oncologist"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100483_bib0006","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9938","key":"10.1016\/j.ctarc.2021.100483_bib0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer\u2013The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.ctarc.2021.100483_bib0008","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.2015.63.7801","article-title":"Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer\u2013Results from the national cancer data base","volume":"33","author":"Killelea","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4 Supplement","key":"10.1016\/j.ctarc.2021.100483_bib0009","first-page":"10","article-title":"Abstract P2-10-10\u2013Lower pathologic complete response rate with dual-HER2 blockage and chemotherapy in African Americans and ethnic minorities","volume":"80","author":"Tiwari","year":"2020","journal-title":"Cancer Res."},{"issue":"4 Supplement","key":"10.1016\/j.ctarc.2021.100483_bib0010","first-page":":06","article-title":"Abstract SS1-06\u2013Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy","volume":"81","author":"Zhao","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100483_bib0011","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer\u2013A systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2021.100483_bib0012","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy\u2013Prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100483_bib0013","doi-asserted-by":"crossref","first-page":"e12658","DOI":"10.1200\/JCO.2020.38.15_suppl.e12658","article-title":"Neoadjuvant chemotherapy in locally advanced breast cancer\u2013Clinicopathological characteristics and correlation with pathological complete response","volume":"38","author":"Choudhary","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100483_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere)\u2013A randomized multicenter, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100483_bib0015","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer\u2013A randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100483_bib0016","article-title":"Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience","volume":"27","author":"Bo\u00e9r","year":"2021","journal-title":"Pathol. Oncol. Res. [Internet]"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100483_bib0017","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12282-019-01037-3","article-title":"Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population","volume":"27","author":"Chang","year":"2020","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100483_bib0018","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-020-05866-1","article-title":"Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)","volume":"184","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2021.100483_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2020.10.014","article-title":"Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer\u2013Population based real world data from the Danish Breast Cancer Group (DBCG)","volume":"54","author":"Berg","year":"2020","journal-title":"Breast"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2021.100483_bib0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/jco.2015.33.15_suppl.531","article-title":"Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab\/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer\u2013The Cleveland Clinic experience","volume":"33","author":"Tiwari","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100483_bib0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE)\u2013A randomized, open-label, multicenter, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100483_bib0022","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000354253","article-title":"Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer\u2013Molecular basis and clinical implications","volume":"8","author":"Giuliano","year":"2013","journal-title":"Breast Care"},{"issue":"46","key":"10.1016\/j.ctarc.2021.100483_bib0023","doi-asserted-by":"crossref","first-page":"e23053","DOI":"10.1097\/MD.0000000000023053","article-title":"Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer","volume":"99","author":"Choi","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctarc.2021.100483_bib0024","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41379-021-00738-5","article-title":"Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer","volume":"34","author":"Katayama","year":"2021","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.ctarc.2021.100483_bib0025","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer\u2013Results from the geparquattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100483_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100483_bib0027","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:35Z","timestamp":1762842155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":27,"alternative-id":["S2468294221001799"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100483","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer\u2013Real-world data from a single center in India","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100483"}}